{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:08:56Z","timestamp":1773155336469,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,7,26]],"date-time":"2013-07-26T00:00:00Z","timestamp":1374796800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s10147-013-0599-5","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T16:56:00Z","timestamp":1374771360000},"page":"662-666","source":"Crossref","is-referenced-by-count":5,"title":["The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer"],"prefix":"10.1007","volume":"19","author":[{"given":"Yui","family":"Tomita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Okadome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Ariyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumi","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,26]]},"reference":[{"key":"599_CR1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ygyno.2009.10.074","volume":"116","author":"JK Chan","year":"2010","unstructured":"Chan JK, Tian C, Teoh D et al (2010) Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 116:307\u2013311","journal-title":"Gynecol Oncol"},{"key":"599_CR2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ygyno.2004.07.056","volume":"94","author":"J Villella","year":"2004","unstructured":"Villella J, Marchetti D, Odunsi K et al (2004) Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol Oncol 94:539\u2013545","journal-title":"Gynecol Oncol"},{"key":"599_CR3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2006.03.018","volume":"103","author":"CA Brewer","year":"2006","unstructured":"Brewer CA, Blessing JA, Nagourney RA et al (2006) Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 103:446\u2013450","journal-title":"Gynecol Oncol"},{"key":"599_CR4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/gyno.2002.6855","volume":"88","author":"RA Nagourney","year":"2003","unstructured":"Nagourney RA, Brewer CA, Radecki S et al (2003) Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 88:35\u201339","journal-title":"Gynecol Oncol"},{"key":"599_CR5","first-page":"237","volume":"28","author":"GJ Peters","year":"2006","unstructured":"Peters GJ, Van Moorsel CJ, Lakerveld B et al (2006) Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int J Oncol 28:237\u2013244","journal-title":"Int J Oncol"},{"key":"599_CR6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/B:DRUG.0000036690.14585.a3","volume":"22","author":"D Tewari","year":"2004","unstructured":"Tewari D, Monk BJ, Hunter M et al (2004) Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest New Drugs 22:475\u2013480","journal-title":"Invest New Drugs"},{"key":"599_CR7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4143\/crt.2011.43.4.217","volume":"43","author":"SH Chun","year":"2011","unstructured":"Chun SH, Lee JE, Park MH et al (2011) Gemcitabine plus platinum combination chemotherapy for elderly patients with advanced non-small cell lung cancer: a retrospective analysis. Cancer Res Treat 43:217\u2013224","journal-title":"Cancer Res Treat"},{"key":"599_CR8","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699\u20134707","journal-title":"J Clin Oncol"},{"key":"599_CR9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.2002.6850","volume":"88","author":"PG Rose","year":"2003","unstructured":"Rose PG, Mossbruger K, Fusco N et al (2003) Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 88:17\u201321","journal-title":"Gynecol Oncol"},{"key":"599_CR10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"599_CR11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","volume":"5","author":"M Markman","year":"2000","unstructured":"Markman M, Bookman MA (2000) Second-line treatment of ovarian cancer. Oncologist 5:26\u201335","journal-title":"Oncologist"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0599-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-013-0599-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0599-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T10:37:32Z","timestamp":1559126252000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-013-0599-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,26]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["599"],"URL":"https:\/\/doi.org\/10.1007\/s10147-013-0599-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,26]]}}}